The independent source for health policy research, polling, and news.
181 - 200 of 1,288 Results
In the past year, opioid settlement money has gone from an emerging funding stream for which people had lofty but uncertain aspirations to a coveted pot of billions being invested in remediation efforts. Here are some important and evolving factors to watch going forward.
Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.
Colorado officials say they havent been able to stand up a program to import drugs from Canada because of drugmaker opposition and the Biden administrations inaction.
States and counties look to expand programs that accept donations of unused surplus drugs from places like nursing homes and hospitals and redistribute them to low-income and uninsured residents.
窪蹋勛圖厙 News gives readers a chance to comment on a recent batch of stories.
The Supreme Court heard arguments over whether the Sacklers, the family behind Purdue Pharma which marketed OxyContin could claim immunity from future lawsuits without claiming bankruptcy.
Despite the prevalence of autoimmune conditions, like the thyroid disease Hashimotos, sometimes finding help can prove frustrating as well as expensive. There are often no definitive diagnostic tests, so patients may rack up big bills as they search for confirmation of their condition and for treatment options.
Floridas Republican Gov. Ron DeSantis and Californias Democratic Gov. Gavin Newsom will square off in a first-of-its-kind debate on Nov. 30. 窪蹋勛圖厙 News compared the political rivals health care positions, showing how their policies have helped or hindered the health of their states residents.
The prevalence of synthetic drugs is undercutting a previously effective and widely embraced opioid use disorder treatment tactic. Now, the model pioneered in Vermont a decade ago and adopted at sites nationwide, especially in hard-to-reach rural areas, is being forced to evolve.
窪蹋勛圖厙 News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Heres a collection of their appearances.
Californias Medicaid program is making it easier for people with diabetes to obtain the supplies and equipment they need to manage their blood sugar, partly by relaxing preauthorization requirements that can cause life-threatening delays.
A rule taking effect Jan. 1 was intended to stop one set of abuses by pharmacy benefit managers, or PBMs, but some pharmacists say its enabling these price brokers to simply do new things unfairly.
Supply problems, a high price tag, and bureaucratic obstacles are slowing the distribution of a therapy that can protect infants from the respiratory syncytial virus. That will leave them unnecessarily at risk of hospitalization this winter, pediatricians fear.
The government has proposed that Medicare fully cover preexposure prophylaxis drugs that prevent HIV, a change that could help America catch up with nations in Europe and Africa that are on track to end new infections decades before the U.S. under its current approach.
The high price of lifesaving tuberculosis drugs makes them inaccessible to many who need them most. On this episode of An Arm and a Leg, hear how a decades-long global fight to reform drug patents is helping to lower the cost.
The CDCs RSV vaccination recommendations beg the question: How much should an immunization that will possibly be given to millions of Americans cost to be truly valuable?
The House finally has a new speaker: Mike Johnson (R-La). Hes a relative newcomer whos been a lower-level member of the House GOP leadership. And while hes an outspoken opponent of abortion and same-sex marriage, his record on other health issues is scant. Meanwhile, the National Institutes of Health appears on track to be getting a new director, and Georgias Medicaid work requirement experiment is off to a very slow start. Alice Miranda Ollstein of Politico and Rachel Cohrs of Stat join 窪蹋勛圖厙 News Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Michael Cannon, director of health policy studies at the Cato Institute, a libertarian think tank.
穢 2026 KFF